Autoscribe Informatics Matrix Gemini LIMS Overview: Features, Pricing & Who It’s For (2026)
Autoscribe Informatics is a LIMS software company with one of the longest track records in the market. Its flagship product, Matrix Gemini LIMS, traces its roots to 1981 when Autoscribe Ltd was founded in the United Kingdom. A 40th anniversary press release published in 2021 confirms the founding year and describes some customers as having been with the product since the early 1990s. The corporate structure around Autoscribe is more complex than its product history, and understanding it matters for buyers: the product and brand have passed through two acquisitions in quick succession. In November 2023, Xybion Digital Inc. (TSX.V: XYBN), a Princeton, New Jersey-based life sciences SaaS company, acquired Autoscribe Informatics for US$12.094 million closing payment, as announced in SEC-equivalent filings on the TSX Venture Exchange and confirmed by Yahoo Finance. Then, in July 2025, Instem — a UK-headquartered supplier of preclinical R&D platforms founded in 1969 — acquired Xybion Digital from Banerjee Group LLC, per a Business Wire press release dated 31 July 2025. The Instem press release confirms that Autoscribe’s LIMS business continues under the Autoscribe brand within Instem. As of April 2026, autoscribeinformatics.com remains an active website, the Autoscribe Informatics brand is in active use, and the product is marketed as “Autoscribe Informatics, a Xybion company” — though the parent is now Instem. Matrix Gemini LIMS has 140+ customers as of the Xybion acquisition announcement (November 2023). The G2 profile has not been actively managed for over a year, per G2’s own notice, which is a visible signal of the transition period. Autoscribe participated in Pittcon 2025 (Boston, March 2025) and Lab Innovations 2024 (Birmingham, October 2024), confirming active commercial activity. This article is based on Autoscribe Informatics’ official website, press releases, and case studies; TSX Venture Exchange filings; Yahoo Finance and Newsfile Corp acquisition announcements; the Instem Business Wire press release (July 2025); G2; Capterra; Sourceforge; the 40th anniversary press release (2021); the Matrix Gemini v6.0 announcement (2021); and Tracxn. Autoscribe Informatics has not reviewed, sponsored, or paid for this article. Understanding the ownership chain — why it matters for buyers Matrix Gemini LIMS is a 40+ year old product that has changed corporate hands twice since late 2023. Buyers evaluating a multi-year LIMS contract should understand this chain before committing. All dates and figures below are sourced from official press releases and public filings: Date Event Detail 1981 Founded Autoscribe Ltd founded in the United Kingdom. The Matrix LIMS product begins development. Early 1990s First customers Some customers confirmed by a 2021 press release to have been with Matrix LIMS since this period. 2011 US entity Autoscribe Informatics formed as the US-facing entity, headquartered in Berkshire County (Tracxn). UK operations continue. Nov 2023 Acquired by Xybion Xybion Digital Inc. (TSX.V: XYBN) acquires Autoscribe Informatics for US$12.094M closing payment plus deferred consideration. Autoscribe had revenue of US$6.18M and EBITDA of US$0.678M in FY ending March 2023 (TSX filing). Autoscribe operated 140+ customer deployments at acquisition. 2024–2025 A Xybion company Autoscribe markets itself as “Autoscribe Informatics, a Xybion company.” Combined Xybion/Autoscribe customer base reaches 350+ across 35 countries (Xybion Q3 2024 filing). Jul 2025 Acquired by Instem Instem acquires all shares of Xybion Digital from Banerjee Group LLC. Instem press release confirms Autoscribe™ brand continues within Instem. Xybion’s former CEO Dr Banerjee noted a “40X MOIC for Xybion shareholders.” Instem was founded in the UK in 1969 and focuses on preclinical R&D. Apr 2026 Current status autoscribeinformatics.com is active. Product marketed as Autoscribe Informatics (brand now under Instem). G2 profile flagged as unmanaged for over a year. Buyer note Two acquisitions in under two years is relevant context for any lab evaluating a 5–10 year LIMS contract. The product has genuine 40+ year continuity and the Matrix Gemini codebase is unchanged. However, buyers should confirm: (1) which entity will hold and service the software licence post-Instem acquisition; (2) whether support, SLA, and upgrade commitments remain as previously contracted; and (3) the product roadmap under Instem’s ownership. These are standard due diligence questions that are more material here than for vendors with stable long-term ownership. At a glance Field Details Product Matrix Gemini LIMS (flagship) + Matrix Gemini LIMS Express (small lab entry) + Matrix Tracker (asset/sample tracking) + Matrix Gemini Stability (stability studies) Brand Autoscribe Informatics — now an Instem company (as of July 2025) Product origin 1981 (Autoscribe Ltd, UK). Celebrating 40 years in business in 2021 per company press release. Founder John Boother, Chairman and Founder. Confirmed in multiple press releases and Tracxn. Offices United Kingdom (HQ), United States (near Boston), Australia (near Adelaide). Worldwide distributor network. Customers 140+ at time of Xybion acquisition (November 2023 press release). Combined Xybion/Autoscribe base: 350+ in 35 countries (Xybion Q3 2024 filing). Revenue (Autoscribe pre-acquisition) US$6.18M revenue, US$0.678M adjusted EBITDA for the fiscal year ending 31 March 2023 (TSX Venture Exchange filing, November 2023). Deployment On-premise (client-managed server), hosted/cloud (third-party server managed by Autoscribe or partner), or hybrid. Both desktop client (LAN) and web browser interfaces available within the same licence. Confirmed on autoscribeinformatics.com. Licensing Perpetual licence (one-off fee) or subscription (quarterly). Both confirmed on G2 pricing page (last updated October 2024). ELN included Built-in ELN module confirmed on Scientific Computing World listing. LES (Laboratory Execution System) and QMS also built in. Key industries Pharmaceutical, medical devices, food & beverage, water/environmental, veterinary, biobanking, mining/materials, contract laboratories Named customers (from case studies) Pixelle Specialty Solutions (paper manufacturing QA, US — customer since 2011, upgraded to v6.x in 2023). Swiss Precision Diagnostics/SPD (medical devices, Geneva — Clearblue maker). Nationwide Laboratories (UK veterinary pathology, 1,100+ tests). CIA Labs (contract lab, Missouri). Tungsten West (mining, UK). University of Iceland Laboratory of Pharmacology and Toxicology (forensic, 4,000–5,000 cases/year). Boston Scientific (named on medical device industry page). Compliance FDA 21 CFR Part 11, ISO 17025, GxP, GLP, GMP, cGxP. Confirmed on autoscribeinformatics.com, G2 listing, and product pages. Pricing Quote-based. Not publicly listed. G2 pricing page states: “available either on-premise or on-line, and may be licensed for a one-off fee or via subscription.”
SciSure Overwiew: Features, Pricing & Who It’s For (2026)
SciSure is a Scientific Management Platform (SMP) that combines ELN, LIMS, and Environmental Health & Safety (EHS) capabilities in a single system. It was formed in January 2025 through the merger of two established companies: SciShield, a Boston-based EHS software provider for research laboratories, and eLabNext, a Groningen, Netherlands-based ELN and LIMS platform that was previously owned by Eppendorf Inc. The merger was announced on 30 January 2025 via Newsfile Corp./EINPresswire and confirmed by Strattam Capital, the private equity firm backing the combined entity. SciSure’s positioning is deliberately distinct from the other LIMS vendors in this series: it is not trying to be the best standalone LIMS. Its core claim is that modern scientific organisations are harmed by running disconnected tools for research documentation, sample management, and safety compliance, and that unifying these into one system reduces administrative burden, improves compliance readiness, and creates a more coherent experience for scientists. The term “Scientific Management Platform” (SMP) was coined specifically to differentiate this broader scope from a traditional LIMS or ELN. The combined company launched with 800+ customer organisations, 550,000+ users, and 37,000+ lab groups across Europe, North America, Asia, and Australia — all figures from the merger press release. In September 2025 SciSure further expanded by acquiring Labfolder and Labregister from Labforward, adding a Berlin-based ELN and inventory system with a strong German research community presence (Newsfile Corp., 11 September 2025). G2 lists SciSure with 193 reviews at 4.2/5, drawn from the combined eLabNext and SciShield user base. As of September 2025, SciSure describes itself as trusted by over 1,000 customers worldwide. This article draws on SciSure’s official website, the merger press release (Newsfile Corp./EINPresswire, 30 January 2025), the Labfolder acquisition announcement (Newsfile Corp., 11 September 2025), the Philip Meer CEO appointment press release (republished on scisure.com, October 2024), the Strattam Capital newsroom, Crunchbase, G2, Capterra, GetApp, Sourceforge, and FitGap. SciSure has not reviewed, sponsored, or paid for this article. How SciSure was formed — understanding the component parts SciSure is a brand-new company built from two organisations with longer independent histories. Understanding those histories matters for buyers evaluating the platform’s maturity, customer base, and product integration status. Date Event Detail ~2010 eLabNext founded Founded by Erwin Seinen and Wouter de Jong as Bio-ITech B.V. in Groningen, Netherlands. Products: eLabJournal (ELN), eLabInventory (LIMS), eLabProtocols. Legal entity: Bio-ITech B.V. (confirmed on Crunchbase). Pre-2025 Eppendorf ownership eLabNext operated as a brand of Bio-ITech B.V., part of Eppendorf Group. eLabNext LinkedIn describes it as “a brand of Bio-ITech BV, part of Eppendorf Group”. QBench’s competitor blog notes eLabNext as “mainly being based in the United States.” 2023 Strattam invests Strattam Capital (Austin/San Francisco private equity) invests in SciShield. The Strattam merger press release states this enabled SciShield to “accelerate innovation” and “expand product offerings, operations, and sales teams.” Oct 2024 Philip Meer named CEO Philip Meer appointed CEO of SciShield. Press release (republished on scisure.com) describes 25+ years of global enterprise software leadership. Strattam Capital Partner Neil Willis quoted endorsing the appointment. Jan 2025 SciSure merger launch SciShield and eLabNext merge and rebrand as SciSure. Newsfile Corp./EINPresswire press release dated 30 January 2025. Combined: 800+ customer organisations, 550,000+ users, 37,000+ lab groups. Eppendorf Inc. endorsed the merger and remains a partner. Nathan Watson (SciShield founder) becomes Chief Strategy Officer. Erwin Seinen becomes CRO. Wouter de Jong becomes CPO. Sep 2025 Labfolder acquisition SciSure acquires Labfolder (ELN) and Labregister (inventory management) from Labforward. Announced Newsfile Corp., 11 September 2025. Products to operate under SciSure brand. Strengthens German research community presence. Apr 2026 Current status SciSure Inc. HQ: 3 Center Plaza, Suite 501, Boston, MA 02108. Over 1,000 customers worldwide (Labfolder acquisition press release). G2 Spring 2026 reports: badges across EHS software, ELN, LIMS, and lab inventory management categories (per SciSure website). Integration context SciSure is less than 18 months old as a merged entity as of April 2026. The merger of SciShield (EHS) and eLabNext (ELN/LIMS) represents two distinct products and teams combining under one brand. A G2 reviewer in a regulated lab environment specifically notes that the “frequency of changes and updates” adds “significant revalidation burden.” Labs evaluating SciSure should assess: (1) how deeply the EHS and ELN/LIMS modules are technically integrated vs. presented under one login; (2) the product integration roadmap; and (3) how Labfolder and Labregister will be incorporated. These are standard due diligence questions for a recently merged platform. At a glance Field Details Brand SciSure (formerly eLabNext and SciShield) Formed January 2025 (merger of SciShield and eLabNext) Pre-merger heritage eLabNext: founded ~2010, Groningen, Netherlands (ELN/LIMS). SciShield: Boston, MA (EHS software for research labs, 27,000+ labs before merger). HQ 3 Center Plaza, Suite 501, Boston, MA 02108, USA CEO Philip Meer (appointed October 2024 at SciShield, leads combined entity) Key leadership Nathan Watson (SciShield Founder, Chief Strategy Officer). Erwin Seinen (eLabNext co-founder, Chief Revenue Officer). Wouter de Jong (eLabNext co-founder, Chief Product Officer). Ownership Backed by Strattam Capital (PE, Austin/San Francisco). Strattam invested in SciShield in 2023 before the merger. Customers 800+ unique customer organisations at merger launch (January 2025). 1,000+ customers worldwide after Labfolder acquisition (September 2025). 550,000+ users at launch. 37,000+ lab groups at launch. Customer profile Fortune 100 biopharma organisations, over one-third of US R1 (top research) academic institutions, biotech, healthcare, oil & gas, food safety, retail (merger press release). Platform Scientific Management Platform (SMP): ELN + LIMS + EHS + Integrations. Also incorporates Labfolder and Labregister (acquired September 2025). Deployment Cloud (hosted in ISO-certified data centres), Private Cloud (dedicated server, custom controls), On-Premises. Confirmed on scisure.com/hosting. Note: EHS capabilities only available on Private Cloud or On-Premises. Compliance 21 CFR Part 11, GDPR, GxP, SOC 2 Type II, HIPAA, ISO 27001. Confirmed on scisure.com/solutions/startup and scisure.com/hosting. ELN included Yes — core component. Originally eLabJournal. Now branded as SciSure ELN. EHS included Yes — environmental health & safety management. Inherited from SciShield. Only fully available on Private Cloud or On-Premises hosting tiers. Pricing Not publicly listed. Quote-based. Academic, Industry, and Startup pricing tiers referenced. Free trial available
eLabFTW Overview: Features, Pricing & Who It’s For (2026)
Two things to know upfront 1. The software is completely free. eLabFTW is open-source (AGPLv3 licence). There is no per-seat charge, no paywalled feature tier, and no vendor lock-in. Every feature is available at no cost. 2. Running it requires a sysadmin. eLabFTW is server software. You cannot install it on a laptop and start using it the next day. It runs on a Linux server, deployed via Docker, and requires a systems administrator to install, configure, and maintain it. If your institution lacks this capacity, Deltablot — the company that backs the project — offers managed hosting. Both paths are covered in this article. eLabFTW is the most widely deployed open-source electronic laboratory notebook in the world. It was created by Nicolas CARPi, a research engineer at the Institut Curie in Paris, who built it to solve a problem he faced in his own lab: no suitable ELN existed that was free, flexible, and respectful of researchers’ data sovereignty. He released eLabFTW as an open-source project and developed it as a side project for years before its adoption reached a scale that led him to create Deltablot, the company that provides commercial hosting and support, in April 2019 (deltablot.com/about). As of April 2026, eLabFTW has thousands of instances running worldwide — the project stopped maintaining a list of institutions because there are too many (doc.elabftw.net/faq). In France, it is the official recommended ELN of the CNRS (Centre National de la Recherche Scientifique), the largest fundamental science agency in Europe, following a competitive selection and deployment process with Deltablot and partner company Easter Eggs. In Germany, it is described in the official documentation as “ubiquitous” at universities and private companies. Community meetings run bi-monthly with participants from institutions across Europe, Asia, and North America. No other ELN in this series — and none in the commercial market — comes close to eLabFTW’s breadth of institutional adoption in academic research. That breadth has a structural reason: when software is free, institutions that could never justify a per-seat licence budget can deploy it. Thousands of research groups at universities, institutes, startups, and public research organisations that could not afford proprietary ELNs have chosen eLabFTW specifically because the barrier to adoption is a server and a sysadmin, not a budget line. This article draws on elabftw.net, deltablot.com, doc.elabftw.net (official documentation), the GitHub repository (elabftw/elabftw), the Deltablot blog, Nicolas CARPi’s startup.info interview (September 2023), his LinkedIn activity, the eLabFTW community meeting summaries, and G2. eLabFTW and Deltablot have not reviewed, sponsored, or paid for this article. Understanding the open-source model — what it means practically eLabFTW is licensed under the AGPLv3 licence. This means: the source code is publicly available on GitHub; you can download, inspect, modify, and deploy it for free; there are no hidden features unlocked by payment; and any modifications you distribute must also be made open-source. The development roadmap and issue tracker are entirely public on GitHub — there is no private backlog, no behind-closed-doors feature development. For lab managers, this has three practical implications that are fundamentally different from every other vendor in this series: The IT dependency Open-source does not mean easy to set up. The official elabftw.net homepage states plainly: “eLabFTW should be installed on a server. This means it is not a software that you can download and install on your computer. It must be installed, configured and maintained by a Systems Administrator. If you’re not familiar with containerized services (Podman/Docker/K8s) and GNU/Linux server administration, we recommend our managed hosted solution.” For lab managers at institutions with central IT infrastructure or a technical research data manager, this barrier is modest. For lab managers at small groups without IT support, the Deltablot PRO Hosting service is the practical path to adoption. At a glance Field Details Software eLabFTW — free, open-source electronic laboratory notebook (AGPLv3 licence) Backing company Deltablot (Paris, France). Founded April 2019 by Nicolas CARPi. Creator Nicolas CARPi, research engineer (Institut Curie). Creator, lead developer, and CEO of Deltablot. Current version 5.5 (deltablot.com blog, 2026). Active development with frequent releases. Primary scope ELN (Electronic Lab Notebook). Also includes a resource/inventory database. Not a full LIMS. Deployment Self-hosted (Docker on Linux server, managed by sysadmin) or Deltablot PRO Hosting (managed SaaS). Software cost Zero. 100% free. All features included. No paywalled tiers. Hosting/support cost Free for self-hosted. Deltablot PRO Hosting: quote-based (four tiers confirmed, no published prices). PRO Support for self-hosters: quote-based. Adoption Thousands of instances worldwide (doc.elabftw.net/faq). CNRS (France) official recommended ELN. Ubiquitous in German universities (official documentation). Named institution supporters: University of Freiburg, Georg-August-University Göttingen, French National Research Institute for Sustainable Development (GitHub sponsors). Languages 21+ languages (elabftw.net). Active translations contributed by community. Key features Experiment documentation, protocol templates, resource/inventory database, file attachments, tags and search, electronic signing, trusted timestamping (RFC 3161), blockchain timestamping (Bloxberg), API, team collaboration, SAML/LDAP SSO, 2FA, audit trail, FAIR data export. Compliance GMP compliance guidance document available (doc.elabftw.net). Trusted timestamping supports regulatory recordkeeping. 21 CFR Part 11: partial — audit trail, electronic signatures, and timestamping are confirmed; full reauthentication at signing (required by §11.200(a)(1)) was an open feature request as of July 2025 (GitHub issue #5782). Regulated labs should validate their specific requirements before deployment. API Full REST API. Official Python client (elabapi-python). Community clients: Perl, LabView, Matlab, R. API workshop available on GitHub. Data sovereignty Data stays on your server (self-hosted) or in Deltablot-managed infrastructure. No telemetry, no tracking cookies (confirmed by Nicolas CARPi, startup.info interview). GDPR-compliant. SecNumCloud option (EU-certified French cloud) available for maximum sovereignty. ELN Consortium Member. Promotes the open .eln interoperability format (RO-Crate-based). G2 profile Listed with verified reviews. G2 reviews describe eLabFTW as easy to use, feature-rich, and good for experiment collaboration. Review count is limited compared to commercial ELNs. Community Bi-monthly community meetings. RDM (Research Data Manager) Club with monthly meetings. Template sharing hub in development (pre-alpha as of January 2026). Active GitHub with many contributors. What eLabFTW does — and what it does not Understanding eLabFTW’s scope is the most important
Labguru ELN LIMS Overview: Features, Pricing & Who It’s For (2026)
Labguru is a cloud-based ELN and LIMS platform built specifically for life science and pharmaceutical labs. It combines an Electronic Lab Notebook, a Laboratory Information Management System, inventory management, and informatics tools in a single system. Since April 2024 it has been owned by Battery Ventures, and as of July 2025 it operates under the newly created Cenevo brand — a merger of Labguru and Titian Software (the UK-based sample management company). The Labguru product name, website, and support infrastructure remain in active use alongside the Cenevo brand, and the article below treats them accordingly. One framing distinction matters upfront: Labguru is widely described — by independent reviewers and competitor analyses alike — as an ELN-first, LIMS-second platform. The Battery Ventures acquisition press release (Business Wire, April 2024) itself positions Labguru’s core strength as lab data management, ELN, and informatics, with LIMS as one component of that broader suite. Labs evaluating Labguru primarily for QC-heavy analytical testing workflows with complex result calculations or batch management should read the “Who it’s for” section carefully. This article draws on labguru.com, the Battery Ventures acquisition press release (Business Wire, 17 April 2024), the Cenevo rebrand press release (PRNewswire, 30 July 2025), the Alantra sell-side advisory announcement, The Connected Lab blog (Thermo Fisher, 26 June 2024), the Labguru 2024 Year in Review blog, G2 (163 reviews, 4.6/5), Capterra, Sourceforge, QBench’s independent competitor analyses (August 2025, January 2026), and CB Insights. Labguru has not reviewed, sponsored, or paid for this article. Corporate history and ownership — the Cenevo context The founding year of Labguru appears as either 2007 or 2008 across different sources: the Battery Ventures Business Wire press release and Alantra both cite 2007; the Cenevo About Us page and CB Insights both cite 2008. The discrepancy likely reflects the difference between when the founding idea was developed and when the legal entity (BioData Inc.) was formally incorporated. The article notes both. Understanding the ownership chain is important context for any multi-year software commitment: Date Event Detail 2007/2008 Founded Founded by Jonathan Gross (founder and CTO) in response to lab data management frustration. Legal entity: BioData Inc. HQ listed at 1900 West Park Drive, Westborough, Massachusetts (CB Insights); Cambridge, MA also cited (finsmes.com). Pre-2024 Holtzbrinck Digital Owned by Holtzbrinck Digital, the digital investment arm of Holtzbrinck Publishing Group (a German publishing house). Also noted as a previous investor: Digital Science (CB Insights). Holtzbrinck described Labguru’s development as positioning it as a “tier-1 lab-management software company.” Apr 2024 Battery Ventures acquires Battery Ventures (Boston-based global technology investment firm) acquires Labguru (BioData Inc.) from Holtzbrinck Digital. Terms undisclosed. Financial advisor to Holtzbrinck: Alantra. Labguru joins Battery’s existing portfolio company Titian Software. CEO Ariel Yarnitsky and founder/CTO Jonathan Gross confirmed to remain in their roles (Business Wire). Jun 2022 Titian/Battery relationship Titian Software (founded 1999, London, UK — sample management software) received a significant investment from Battery Ventures in June 2022 (Cenevo press release). This predates the Labguru acquisition. Jul 2025 Cenevo rebrand Titian Software and Labguru rebrand together as Cenevo (PRNewswire, 30 July 2025). The combined entity is headquartered in London, UK. Labguru and Mosaic (Titian’s sample management platform) continue as products under the Cenevo brand. New CEO: Keith Hale. Jonathan Gross becomes Chief Product Officer at Cenevo. Over 950 customers combined; 45,000+ scientist users; 200+ staff; offices in UK, US, Israel, and Poland. Apr 2026 Current status labguru.com is active. Product marketed under the Labguru brand within Cenevo. G2 listing: “Labguru ELN LIMS” — 163 reviews, 4.6/5. Thermo Fisher Scientific partnership active (signed June 2024). Cenevo and Labguru — what it means for buyers The Cenevo rebrand (July 2025) brings Labguru and Titian’s Mosaic sample management platform under one corporate roof. The Cenevo press release explicitly commits that “the trusted Labguru and Mosaic solutions are and will continue to be a core part of our identity, both stand-alone or combined.” Labs evaluating Labguru in 2026 are buying into a Battery Ventures-backed, Cenevo-operated platform. If combined Labguru+Mosaic sample management coverage is relevant to your organisation, the Cenevo relationship is worth exploring. If you only need ELN/LIMS, Labguru operates as a standalone product. At a glance Field Details Product Labguru ELN LIMS (cloud-based) Legal entity BioData Inc. / BioData Ltd. (Labguru trademark registered to BioData Ltd. per QBench) Founded 2007 (Business Wire, Alantra) or 2008 (Cenevo About Us, CB Insights) — both cited Founder/CTO Jonathan Gross (founder). As of July 2025: Chief Product Officer at Cenevo. CEO Ariel Yarnitsky (CEO as of Battery acquisition, April 2024). Keith Hale is CEO of the combined Cenevo entity. HQ (Labguru) Westborough, MA, USA (CB Insights). Cambridge, MA also referenced (finsmes.com). Parent company Cenevo (since July 2025). Backed by Battery Ventures. Previously owned by Holtzbrinck Digital. Cenevo HQ London, UK Users 120,000+ scientists (Battery acquisition press release, April 2024). 95,000+ on Capterra. 45,000+ across combined Cenevo (Labguru + Mosaic). Customers 950+ combined Cenevo customers (Cenevo press release). Labguru described as serving “hundreds of thousands of scientists” in Battery press release. Industries Biotech, pharma, agritech, foodtech, chemical manufacturing, academic research, and industrial labs. Confirmed across labguru.com and Battery press release. Platform scope ELN + LIMS + Inventory Management + Equipment Management + Informatics/AI tools + Protocol Management + Automation + API Primary positioning ELN-first. Multiple independent sources characterise Labguru as ELN-first with LIMS as a secondary component. Deployment Cloud-only. Confirmed across all sources. Web-based; accessible from desktops and mobile devices. No on-premise option confirmed. Languages English, French, Hebrew, Russian, Spanish (Sourceforge) Compliance FDA 21 CFR Part 11, GxP (GLP, GMP). ISO 27001 certified (SoftwareAdvice). Confirmed on labguru.com and multiple review platforms. Pricing Not publicly listed. Quote-based. Academic, Industry, and Startup tiers referenced across review platforms. Free trial available (Sourceforge, confirmed multiple sources). G2 rating 4.6/5 from 163 reviews (G2 November 2025 lab category listing). LIMS-specific sub-listing: 73 reviews as of January 2026 (QBench Best LIMS 2026 article). Top G2 positive themes: Customer Support (24), Lab Management (19), Inventory Management (19), Ease of Use (19), Organisation (16). Integrations SAP QM (deepened 2024
STARLIMS Overview: Features, Pricing & Who It’s For (2026)
STARLIMS is one of the oldest names in LIMS with one of the most complex ownership histories in the market. Founded in Israel in 1986 by Itschak Friedman and Dinu Toiba, it held an IPO in 2007 and was acquired by Abbott Laboratories in 2009 for $123 million (Wikipedia). Abbott retired the brand for 12 years before Francisco Partners acquired the business in July 2021 and relaunched STARLIMS as an independent brand. In January 2026, Francisco Partners sold STARLIMS to Turn/River Capital — a software-focused private equity firm — per a Business Wire press release dated 13 January 2026. CEO Trey Cook remains in place. As of April 2026, STARLIMS is a Turn/River Capital portfolio company, headquartered in Hollywood, Florida. It serves more than 1,100 customers across 2,000+ laboratories in 85+ countries (Turn/River press release and LinkedIn), spans life sciences, manufacturing, public health, clinical diagnostics, food & beverage, chemical, oil & gas, and more, and holds the #1 LIMS position on G2 with 158 reviews at 4.5/5 as of the G2 Fall 2025 report. This article is based on STARLIMS’s official website and press releases, Wikipedia, Business Wire announcements (Labstep acquisition 2023, LPH launch 2024, QM Essentials 2025, Turn/River investment 2026), G2, Capterra, PitchBook, and LinkedIn. STARLIMS has not reviewed, sponsored, or paid for this article. At a glance Field Details Vendor STARLIMS Corporation (STARLIMS Technologies) Founded 1986 in Israel by Itschak Friedman and Dinu Toiba (Wikipedia) HQ Hollywood, Florida, USA CEO Trey Cook Employees ~219 (PitchBook). ~201–500 (LinkedIn). ~85+ countries served. Ownership Turn/River Capital (PE, investment announced January 2026). Previously Francisco Partners (acquired from Abbott, July 2021). Key corporate history 1986: Founded (Israel). 2007: IPO. 2009: Acquired by Abbott Labs for $123M. 2021: Sold to Francisco Partners. Aug 2023: Acquired Labstep ELN. Jan 2024: Launched LPH 1.0 (public health LIMS). Oct 2025: Launched QM Essentials (SMB SaaS LIMS). Jan 2026: Sold to Turn/River Capital. Platform scope LIMS + ELN (Labstep) + LES (Laboratory Execution System) + SDMS (Scientific Data Management System) + Advanced Analytics 2.0 Key industries Life sciences, pharmaceuticals, CDMOs, food & beverage, chemical & agrochemical, oil & gas, consumer goods, contract testing, public health, clinical diagnostics Named customers Bayer (14+ years, CropScience regulatory and GxP labs — 2024 Rewind blog). DuPont (R&D lab ecosystem — 2023 Rewind blog). Sasol (manufacturing, 2023). CDC and 12 US state health authorities (by 2005 per Wikipedia). Elypta, Francis Crick Institute (Labstep ELN, starlims.com). Newform Foods (Labstep ELN). Deployment On-premise, cloud-hosted (managed by STARLIMS), and SaaS. Cloud includes AWS hosting, HIPAA and GDPR compliance, 99.9% availability. QM Essentials is a pure SaaS out-of-the-box product. ELN included Yes — Labstep (acquired August 2023). Modern cloud R&D ELN sold separately and as part of integrated platform. Also a legacy in-platform ELN (noted in reviews as less user-friendly). Compliance 21 CFR Part 11, GxP, GMP, GLP, ISO 17025, HIPAA, GDPR. Confirmed on starlims.com and Capterra cloud description. Pricing Not publicly listed. Enterprise: quote-based. QM Essentials (SMB SaaS): quote-based but deployable in 4–6 weeks. Public sector contracts suggest significant implementation costs for complex deployments. G2 rating #1 LIMS on G2. 4.5/5 from 158 reviews (G2 Fall 2025 report per STARLIMS blog). Leader in LIMS, SDMS, and ELN Grid reports. Momentum Grid Leader. Mid-market badges in Implementation, Usability, and Relationship indices. Free trial Not confirmed. What STARLIMS does STARLIMS positions its platform as a unified R&D Quality Manufacturing Informatics Platform — a suite covering the full laboratory value chain from R&D through QC and manufacturing to commercial release. Its core components, all documented on starlims.com and confirmed in Business Wire press releases: All modules connect in what STARLIMS calls the R&D Quality Manufacturing Informatics Platform — positioning one vendor as able to support a company from first experiment through to commercial batch release. The 2024 Rewind blog confirms Bayer CropScience as the flagship use case for this end-to-end vision. Labstep vs legacy ELN STARLIMS now has two ELN products: Labstep (the acquired cloud-native R&D product) and an older in-platform ELN. G2 and Capterra reviews reference the legacy ELN as “not very user-friendly” with a reviewer noting STARLIMS is “missing the boat on ELN implementation.” The Labstep product is the current strategic investment and is well-reviewed independently. Labs evaluating STARLIMS for ELN should clarify which product applies to their deployment and whether Labstep is included or priced separately. Deployment and compliance STARLIMS supports three deployment models, confirmed on Capterra and starlims.com: Compliance standards confirmed on starlims.com and Capterra include: FDA 21 CFR Part 11, GxP (GMP, GLP), ISO 17025, HIPAA, and GDPR. The Capterra cloud offering specifically confirms HIPAA and GDPR as included in the managed cloud tier. Pricing STARLIMS does not publish pricing publicly. Enterprise platform pricing requires a direct quote. Two real-world data points from public sector procurement records, cited by an independent Scispot analysis blog: These figures are from public sector contracts, which typically reflect competitive bid environments and may not be representative of commercial pricing. They do, however, confirm that complex enterprise STARLIMS implementations involve substantial total cost of ownership. QM Essentials (SMB SaaS) is designed to reduce this — no pricing is published for it either, but its 4–6 week deployment timeframe implies materially lower implementation cost than the enterprise product. Pricing note The only independent pricing signal for STARLIMS in the market comes from public sector procurement disclosures. Commercial pricing is entirely quote-based and will depend heavily on user count, modules selected, deployment model, and implementation scope. Labs should request a total cost of ownership estimate — including implementation, training, and annual support — not just a licence fee. Who STARLIMS is designed for Based on named customers, industry pages, and G2 review profile, STARLIMS is strongest for: STARLIMS is less commonly the right fit for: What users say STARLIMS holds G2’s #1 LIMS position with 4.5/5 across 158 reviews (G2 Fall 2025 report). It is also a Leader in G2’s SDMS and ELN categories, and holds the Momentum Grid Leader badge. Mid-market badges were added in Fall 2025 across Implementation,
Sapio Sciences Review: Features, Pricing & Who It’s For (2026)
Sapio Sciences is a laboratory informatics platform founded in 2004 by Kevin Cramer in Baltimore, Maryland. The company’s origins are in genomics and machine learning — its first product, Exemplar Analytics, integrated over 50 algorithms for genetic data analysis. In 2007, Sapio entered the LIMS market with Exemplar LIMS, and in 2017 became, according to Wikipedia, the first company to integrate a full-featured, web-based Electronic Lab Notebook with a LIMS on a single unified platform. In December 2022, GHO Capital Partners — a London-based private equity firm specialising in global healthcare — took a majority stake in the company. The investment press release confirmed named customers at the time of investment as Bristol Myers Squibb, GSK, Johnson & Johnson, Charles River, and LabCorp. GHO’s stated rationale was to fund international expansion, particularly into Europe, and accelerate AI development. Today, Sapio describes itself as an “AI-native” lab informatics platform, positioning its LIMS, ELN (Sapio ELaiN), and Scientific Data Cloud as a unified system purpose-built for biopharma R&D, CROs, and clinical diagnostics. Its momentum in 2024–2025 has been notable: it secured the Wellcome Sanger Institute as a customer (December 2025), Schrödinger (January 2025), AstraZeneca spoke at its annual SapioCon conference (2025), and it integrated NVIDIA BioNeMo into its platform (March 2025). This article draws exclusively on Sapio’s official website, Wikipedia, GHO Capital’s press releases, Business Wire announcements, G2, Sourceforge, and independent analyst sources. Sapio Sciences has not reviewed, sponsored, or paid for this article. At a glance Field Details Vendor Sapio Sciences, Inc. Founded 2004 by Kevin Cramer Headquarters Baltimore, Maryland, USA. Offices in York PA, Fort Lauderdale FL, and London, UK. CEO & CTO Kevin Cramer (founder) Ownership Private equity backed. GHO Capital Partners took a majority stake in December 2022. Platform scope LIMS (Sapio LIMS®) + ELN (Sapio ELaiN™) + Scientific Data Cloud — all on one unified, no-code/low-code architecture Deployment Cloud-native SaaS. AWS-hosted. Confirmed no on-premise offering in current platform. Key industries Biopharma R&D, biotechnology, CRO, clinical and molecular diagnostics, biomanufacturing/GMP, NGS Named customers Bristol Myers Squibb, GSK, J&J, Charles River, LabCorp (GHO press release, 2022). Oxford Biomedica (2023). Schrödinger, LabConnect (2025). Wellcome Sanger Institute (December 2025). Compliance 21 CFR Part 11, EU Annex 11, GxP (full GxP validation awarded 2024). SOC 2 Type 2 (August 2024). HIPAA/HITECH (August 2024). HDS — Hébergeur de Données de Santé (January 2025). ISO 27001 not confirmed. ELN included Yes — Sapio ELaiN is a core product, not an add-on. Integrated with LIMS in a single platform. AI assistant ELaiN — first launched in 2023. Third-generation version integrates AWS Bedrock (November 2024), NVIDIA BioNeMo (March 2025), and a partner ecosystem including CCDC, Cadence Molecular Sciences/OpenEye, and Optibrium (January 2026). Pricing Not publicly listed. Quote-based. Multiple editions including a free Bronze entry tier (academic/small startup). Paid tiers require direct engagement. Languages English, French, German, Italian, Portuguese, Spanish (per Sourceforge listing) Support Phone, 24/7 live support, online. Training included with purchase (per Sourceforge). Annual SapioCon user conference. G2 Listed on G2 with multiple editions (LIMS, ELN, Scientific Data Cloud). Reviews are present but review count is modest compared to more marketing-mature LIMS vendors. What Sapio Sciences does Sapio’s platform is built around three integrated products that share a single cloud-native architecture and data foundation. The company’s core claim is that this unification eliminates the need to integrate separate LIMS, ELN, and SDMS systems from different vendors: Additional scientific tools built into the platform, per the Sapio website, include CRISPR design, genome browsing, vector modification, plasmid design, compound design, 3D plating, and flow cytometry data management. Electronic Batch Record (EBR) capabilities were released in October 2024. SapioCon 2025 context Sapio’s annual conference (SapioCon) in 2025 featured presentations from AstraZeneca, Johnson & Johnson, CureVac, Olink, Amazon AWS, and IQVIA. AstraZeneca’s Global Head of IT for Research, Amrik Mahal, presented on how AstraZeneca uses Sapio informatics to drive its digital transformation in drug discovery. This is referenced in Sapio’s resource library blog (“Making a Difference: Digital Transformation and LIMS in Pharma (AstraZeneca)”) but a formal press release confirming the customer relationship has not been published by Sapio as of April 2026. Compliance and regulatory support Sapio’s compliance posture has strengthened substantially in 2024–2025. All of the following are confirmed through official press releases, Wikipedia, and Business Wire announcements: Validation note Sapio’s full GxP validation (2024) means the platform has been formally validated for use in regulated environments. Sapio’s GMP LIMS is described on its website as “out-of-the-box support for batch management, QC testing, stability and environmental monitoring, and automatic COA generation.” Labs in regulated GMP manufacturing should request Sapio’s full validation package and documentation scope before purchase, as the degree of vendor-supplied vs. lab-supplied validation evidence varies by deployment context. Deployment and architecture Sapio is a cloud-native SaaS platform. The Wikipedia article and GHO Capital press release both confirm it operates as a SaaS business. The platform is built on AWS — AWS Bedrock integration was confirmed in November 2024, and AWS was a speaker at SapioCon 2025. No on-premise deployment option has been confirmed in publicly available documentation. The platform is described as no-code/low-code: workflow designers, rules engines, and UI design tools allow labs to configure the system without developer involvement. Where custom code is required, ELaiN can automatically generate Python configuration code from natural language prompts. The system supports hundreds of concurrent users and multi-site deployments, per the GHO Capital investment documentation. Integration is supported through APIs, webhooks, and direct instrument interfaces. The Wellcome Sanger Institute deployment (December 2025 press release) specifically calls out “advanced workflow automation and equipment integration” including the ability to connect to new, cutting-edge instruments — a practical validation of the platform’s integration capability at enterprise scale. Key milestones: 2022–2026 This timeline draws exclusively on Wikipedia, Business Wire, and Sapio’s own press releases: Pricing Sapio does not publish pricing publicly. All paid tiers require a direct quote. G2 lists five pricing editions; Sapio’s website and G2 confirm a free Bronze tier exists. Based on G2’s pricing page and independent analysis: Pricing
QBench LIMS Overview: Features, Pricing & Who It’s For (2026)
QBench is a cloud-based Laboratory Information Management System (LIMS) founded in 2016 and headquartered in Newark, Delaware. According to the company’s own blog and comparison pages, it was started by lab owners and software investors with over 30 years of combined laboratory experience — a founding context that explicitly shapes the product’s direction toward lab-manager usability rather than enterprise IT complexity. The platform sits in the mid-market of the LIMS space: more fully featured and configurable than entry-level tools, more accessible and faster to implement than legacy enterprise platforms. It has built a notable track record on G2, holding the #1 position on G2’s Highest-Rated LIMS list and earning the Easiest to Use designation, with 133 verified reviews as of January 2026 and a 4.5/5 average rating. QBench is privately owned — not venture-capital backed — by a group of families and software investors. The company states this gives it a long-term time horizon and the ability to prioritise customer outcomes over growth metrics. Approximately 85% of employees are based in North America as of 2025. This article is based on QBench’s official website and pricing page, G2 and Capterra reviews, Software Advice, Crunchbase, CB Insights, and independent competitor analysis. QBench has not reviewed, sponsored, or paid for this article. At a glance Field Details Vendor QBench Inc. Founded 2016 Headquarters Newark, Delaware, USA Ownership Privately owned — family and software investors. Not VC-backed. Employees ~85% North America-based (QBench blog, 2025). Global team. Deployment Cloud-only (SaaS). Hosted on AWS. No on-premise option. Platform scope LIMS core + integrated QMS, Inventory Management, Customer Portal, Billing, REST API, Analytics/BI integrations Key industries Biotech & life sciences, food & beverage, environmental, agricultural, clinical & diagnostics, materials & manufacturing Compliance ISO 17025:2017, HIPAA, 21 CFR Part 11, CLIA, SOC 2 Type II (annual audit, no exceptions recorded) ELN included Not a core feature. Protocols (LES) are included. QBench positions itself as a LIMS-first platform. Pricing Publicly listed. Starts at $275/user/month (Foundation, billed annually, 5-user minimum). See pricing section below. Implementation Weeks, not months. Training: $5–$10K. Professional Services: varies by scope (per QBench pricing page). Release cadence Software updates every two weeks (per QBench’s own blog), enabling rapid feature delivery. G2 rating 4.5/5 — 133 reviews (January 2026). #1 Highest-Rated LIMS, #1 Easiest to Use, Momentum Leader (Winter 2026). 5 first-place rankings in G2 Spring 2026 report. Free trial No free trial. Demo available on request. What QBench does QBench describes itself as a Lab Operating System — a positioning that signals its ambition to go beyond pure sample tracking and serve as the central operational hub for the entire testing workflow. The platform is built around a no-code configuration philosophy: labs can modify workflows, add custom fields, create automations, and build report templates without writing code or engaging vendor professional services for every change. Core capabilities documented on qbench.com include: QBench releases software updates every two weeks — a notably faster cadence than most LIMS vendors, which typically release quarterly or less frequently. The company publishes a customer feature request board where users can submit, vote on, and track feature ideas. Deployment and security QBench is a cloud-only SaaS platform hosted on AWS. There is no on-premise option. Data transmitted between the lab and QBench is encrypted using HTTPS. The platform undergoes an annual SOC 2 Type II audit — a press release published in 2023 confirmed the audit was completed with no exceptions, and the company commits to annual repetition. Security and access controls documented on QBench’s compliance page include: SSO note Single Sign-On (SSO) and Multi-Factor Authentication (MFA) are only included in the Enterprise tier, which requires a custom quote. Labs on lower tiers who require SSO for IT policy or regulated environment reasons should factor Enterprise pricing into their evaluation. This is confirmed in the CloudLIMS vs QBench competitive analysis published by CloudLIMS. Compliance and regulatory support QBench’s compliance capabilities are documented on a dedicated security and compliance page at qbench.com. The platform supports: Validation note QBench offers access to third-party validation services through what it calls the QBench Vendor Alliance — connecting regulated customers with external vendors for validation. Unlike some enterprise LIMS providers, QBench does not supply IQ/OQ/PQ documentation directly; validation is the customer’s responsibility. Labs in 21 CFR Part 11 or GxP environments should confirm the scope of validation support before committing. This is noted in an independent comparison blog published by Thirdwave Analytics in January 2026. Pricing — one of the few LIMS vendors with published rates QBench is unusual in the LIMS market for publishing its pricing publicly. All figures below are taken directly from qbench.com/pricing and QBench’s own blog posts. These are the only vendor-confirmed pricing figures available and should be verified at the time of purchase. Plan Price / user / month Min. users Key additions vs tier below Foundation $275 / user / month 5 users min. Core LIMS: workflows, sample tracking, reports, no-code config, basic analytics Growth $325 / user / month 5 users min. Adds: Customer Portal, Inventory Management, Instrument Integration, REST API Advanced $425 / user / month 5 users min. Adds: QMS (CAPA, Doc Control, Training), Billing, Dropbox integration Enterprise Custom quote Custom Adds: SSO, MFA, dedicated support, custom SLAs Per QBench’s own hidden costs blog post, the Foundation plan starts at $16,500/year for a 5-user lab (billed annually). The company states volume discounts are available as labs grow, though specific volume discount thresholds are not published. Initial training is billed upfront at $5–$10K. Professional services for data migrations, third-party integrations, or custom work are billed separately as work is completed, and are delivered by Technical Account Managers who are described on the pricing page as former lab staff. Tier consideration Labs requiring QMS functionality — including CAPA management and document control — must reach the Advanced tier at $425/user/month. For a 5-user lab, this is $25,500/year before training and professional services. Labs requiring SSO and MFA must reach the Enterprise tier with a custom quote. Regulated labs
Benchling Overview: Features, Pricing & Who It’s For (2026)
Benchling was founded in 2012 in San Francisco by Sajith Wickramasekara and Ashu Singhal, two MIT alumni who met while working in biology research labs. The company’s stated mission from the outset was to build software purpose-built for biology — not adapted from generic laboratory management tools. Today, according to its own press releases, Benchling serves more than 1,300 biotech companies worldwide, including more than half of the top 50 global biopharma companies, and more than 200,000 scientists rely on its platform. The company has raised a total of $418 million in funding across 11 rounds, per PitchBook. Its last published valuation was $6.1 billion following a Series F in November 2021 — a figure that has not been publicly updated since. Key investors include Altimeter Capital, Tiger Global, Benchmark, ICONIQ Capital, Lux Capital, Franklin Templeton, and Thrive Capital. Benchling sits at an important intersection in the lab software market: it is neither a traditional LIMS nor a pure ELN. The company describes itself as a unified R&D Cloud — a platform that brings electronic notebook, molecular biology tools, sample management, workflow orchestration, and AI into a single cloud-native system built specifically for life sciences research and development. This article is based exclusively on Benchling’s official documentation, press releases, AWS Marketplace listing, PitchBook, Sacra research, G2, and independent analysis from Clarkston Consulting. No payment or sponsorship from Benchling is involved. At a glance Field Details Vendor Benchling, Inc. Founded 2012 Headquarters San Francisco, California, USA Co-founders Sajith Wickramasekara (CEO) and Ashu Singhal (President) Employees ~797 (PitchBook, 2026) Funding raised $418 million across 11 rounds (PitchBook). Last published valuation: $6.1 billion (Series F, November 2021) Estimated ARR Sacra estimated $210 million annualised recurring revenue as of May 2024, up 27% year-on-year Users 200,000+ scientists across 1,300+ companies and 7,500 academic institutions (Benchling press releases, 2025) Deployment Cloud-only (SaaS). No on-premise option. Platform scope Notebook (ELN), Molecular Biology, Registry, Inventory, Requests, Workflows, Insights, Lab Automation, Benchling AI Key industries Biotech, biopharma, academic research, agricultural biotech, synthetic biology Named customers Merck, Moderna, Sanofi (1,500+ scientists, 30 teams — June 2024 press release) Compliance 21 CFR Part 11, EU Annex 11, GxP (via Validated Cloud), ISO/IEC 27001:2022, SOC 2 Type 2, GDPR, CCPA, NIST, C5 ELN included Yes — Notebook is one of seven integrated applications, not an add-on Pricing Not publicly listed. Quote-based enterprise contracts. Academic use: free. Startup pricing last published in 2020 at ~$20,000/year for 5 users. G2 rating 4.5 / 5 — Leader badge in LIMS and ELN categories. Most recent review: January 2025 (per QBench) Free tier Yes — free for academic scientists, including Benchling AI (launched October 2025) Recent acquisitions ReSync Bio and Sphinx Bio — both acquired August 2025 to accelerate AI roadmap What Benchling does Benchling describes its platform as the R&D Cloud — a unified, cloud-native system built around the specific needs of biology-driven research. Unlike traditional LIMS that were designed primarily for structured, repetitive QC workflows, Benchling’s architecture prioritises the flexibility and collaboration needs of early-stage and mid-stage biotech R&D. Its platform consists of seven integrated applications, all sharing a common data layer: The platform also exposes well-documented REST APIs, event-triggered integrations, and a built-in Data Warehouse, confirmed on both the Benchling website and its AWS Marketplace listing. New capabilities announced at Benchtalk 2025 include custom Python and R scripting running natively inside the platform. Important distinction Benchling is often described as a LIMS, but its architecture prioritises R&D flexibility over the structured QC workflows that define traditional LIMS. Independent consultancy Clarkston Consulting states clearly that Benchling “does not provide adequate support for quality control (QC) activities such as batch management, product specifications, and report generation” at commercial scale. Labs transitioning from early R&D to regulated manufacturing QC should evaluate whether Benchling’s Validated Cloud meets their full compliance requirements before committing. Deployment Benchling is a cloud-only platform — there is no on-premise option. All data is hosted in Benchling’s cloud infrastructure, which maintains ISO/IEC 27001:2022 certification (with extensions ISO/IEC 27017:2015 and 27018:2019) and SOC 2 Type 2 attestation, confirmed on Benchling’s Trust page. The platform uses AES 256-bit encryption at rest and TLS 1.2 or higher in transit, and operates a Zero Trust security policy. There are two tenant types: The AWS Marketplace listing confirms the platform is 21 CFR Part 11 compliant. Single Sign-On (SSO) with multi-factor authentication (MFA) is supported, and customers can configure access control via their own SSO provider. Compliance and regulatory support Benchling has published a whitepaper specifically addressing GxP computer systems validation considerations. Key compliance capabilities, verified across Benchling’s Trust page, Validated Cloud product page, and the GxP whitepaper: Validation note Validated Cloud tenants receive quarterly releases with Validation Plan and Impact Assessments from Benchling. The GxP whitepaper describes the split between what Benchling is responsible for and what the customer must complete to maintain a validated state. Clarkston Consulting notes that while this “reduces customers’ validation burden,” labs must still complete their own validation activities. The full validation responsibility is shared, not transferred to Benchling. Pricing Benchling does not publish current pricing. The last pricing information published on Benchling’s website was in 2020, when the professional plan was listed at around $20,000 per year for five users. That figure has not been officially updated. Sacra’s independent financial research (May 2024) estimates an average revenue per customer of approximately $175,000 as of May 2024, up from $125,000 in 2017–2018, reflecting expansion within existing accounts. With 1,200 commercial customers as of May 2024 and $210 million in estimated ARR, this average is consistent with mid-to-large enterprise contracts. Benchling offers a free plan for academic scientists, extended in October 2025 to include free access to Benchling AI. For commercial labs, pricing is available on request. Pricing note Independent sources consistently describe Benchling as one of the more expensive platforms in the biotech R&D space. One 2025 analysis (cited by IntuitionLabs, noting it was sponsored by a competitor) suggests per-user costs in the range of $5–$7k per user per year.
LabVantage LIMS Overview: Features, Pricing & Who It’s For (2026)
LabVantage Solutions has been building laboratory informatics software for over four decades. Founded in 1981 as Laboratory MicroSystems — a company that started in a graduate school at Rensselaer Polytechnic Institute and made the Inc. 500 list by 1987 — the company was renamed LabVantage in 1997 and is today headquartered in Somerset, New Jersey. Wikipedia describes it as the third-largest LIMS provider in the world. The platform has grown from a sample-tracking tool into a broad laboratory informatics suite combining LIMS, Electronic Lab Notebook (ELN), Laboratory Execution System (LES), Scientific Data Management System (SDMS), and embedded analytics under a single architecture. In October 2024, Frost & Sullivan named LabVantage its Global LIMS Company of the Year — the second consecutive year the company topped that ranking for growth and innovation. In November 2025, LabVantage was awarded a $22.3 million, ten-year contract by the U.S. Department of Homeland Security’s Customs and Border Protection (CBP) to deliver a next-generation forensic LIMS — its first DHS project and one of the largest publicly disclosed government LIMS contracts of the year. This article draws exclusively on LabVantage’s official documentation, press releases, Wikipedia, PitchBook, G2, Capterra, and independent analyst sources. No payment or sponsorship from LabVantage is involved. At a glance Field Details Vendor LabVantage Solutions, Inc. Founded 1981 (as Laboratory MicroSystems; renamed LabVantage in 1997) Headquarters Somerset, New Jersey, USA — global offices worldwide Employees ~1,223 globally (PitchBook, 2024) Customers More than 1,500 sites across more than 750 customer organisations Implementations More than 2,000 completed worldwide (press release, November 2025) Platform scope LIMS + ELN + LES + SDMS + Analytics — all within a single architecture and licensing model Deployment options On-premise, cloud-hosted, SaaS. SaaS environment runs on AWS in the EU (per Nordic partner documentation) Technology 100% browser-based (zero footprint); Java/JavaScript core; no proprietary scripting language required Pricing Not publicly listed. Quote-based. Tiered model (Express, Standard, Enterprise) per Technology Evaluation Center. Key industries Pharma, biopharma, biobanking, food & beverage, oil & gas, forensics, clinical/diagnostics, CPG, government Compliance 21 CFR Part 11, EU Annex 11, GxP (GLP/GMP), GAMP5, ISO/IEC 17025:2017, ISO 27001, ISO 9001 ELN included Yes — fully integrated within the platform, not a separate product G2 rating 19 reviews (limited sample) — Leader badge in LIMS and ELN categories Capterra rating Listed; small number of reviews on platform Awards (recent) Frost & Sullivan Global LIMS Company of the Year 2024; Frost Radar LIMS Growth & Innovation Leader 2023 & 2024 Free trial No. Demo available on request. What LabVantage LIMS does A key differentiator of LabVantage is that its LIMS, ELN, LES, SDMS, and analytics capabilities share a single architecture, a common user interface, and a single licensing model. This matters in practice: data does not need to move between separate systems, and users operate within one consistent environment from bench to boardroom — a phrase used on the company’s homepage. Based on official documentation and partner documentation, the core functional scope includes: The platform is built on Java and JavaScript — no proprietary scripting language — and is 100% browser-based with zero desktop footprint, supporting hundreds of concurrent users. This is a deliberate architectural contrast to some competitors that rely on proprietary configuration languages. Deployment options LabVantage supports three deployment models, all providing access to the full platform scope: LabVantage acquired SEIN Infotech in 2024, and has expanded into Colombia, Brazil, South Korea, and Hong Kong, per Frost & Sullivan’s 2024 award announcement. The company’s professional services organisation grew by more than 80% over three years, which is relevant to labs evaluating implementation support capability. Compliance and regulatory support LabVantage publishes a detailed white paper on its 21 CFR Part 11 and EU Annex 11 compliance posture, which is one of the more transparent compliance disclosures in the LIMS market. Verified capabilities documented in that white paper and in the DHS CBP press release include: Validation note LabVantage Pharma is described as a pre-validated SaaS solution, with LabVantage’s professional services team supporting validation work including instrument integration and master data management. For the enterprise platform, validation remains a customer responsibility, though LabVantage provides pre-validation materials for regulated industries as part of its accelerator packages. Pricing LabVantage does not publish pricing on its website. Pricing is quote-based and varies by deployment model, number of users, industry, and module selection. Technology Evaluation Center describes a tiered model with Express, Standard, and Enterprise versions aligned to different organisation sizes and requirements. The SaaS model removes upfront infrastructure cost in exchange for an ongoing subscription. For on-premise deployments, infrastructure costs — including server hardware, database licensing, and networking — are borne by the customer. Pricing note LabVantage is consistently positioned as a mid-to-enterprise tier platform. One Capterra reviewer notes it is “worth the money” while flagging the complexity of extracting data without consultant support. TEC’s analysis states that “for some customers, LabVantage has delivered ROI in less than 12 months,” but also notes that “initial setup investment and customising workflows require upfront effort.” Budget for implementation, validation, and training in addition to licensing when building a total cost of ownership model. Who LabVantage LIMS is designed for Based on verified customer data, industry documentation, and the DHS contract, LabVantage serves a wide cross-section of laboratory environments. Named industries on the vendor’s website and in press releases include pharmaceuticals, biopharma, biobanking, medical devices, food and beverage, consumer packaged goods, oil and gas, forensics, diagnostics, academia, and government. In India, confirmed customers include GAIL, Indian Oil Corporation, and Reliance Industries, per Wikipedia. Historical US customers noted on Wikipedia include Pfizer and Unilever. The DHS CBP contract expands its government and public sector footprint. The platform is most commonly chosen by: What users say G2 lists 19 verified reviews for LabVantage (a smaller sample than some competitors). Capterra has a limited number of reviews. The following themes are drawn from both platforms and from TEC’s independent analysis. Frequently praised Frequently criticised Quick verdict Best for Mid-to-large regulated laboratories seeking a unified platform — LIMS, ELN,
LabWare LIMS Overview: Features, Pricing & Who It’s For (2026)
LabWare is one of the longest-standing names in laboratory informatics. Founded in 1987 and headquartered in Wilmington, Delaware, the company has been building LIMS software for over 35 years. According to its own published data, LabWare now serves more than 10,000 laboratories in over 125 countries, and counts organisations including GSK, Pfizer, Hershey, Caterpillar, and Chevron among its customers. In 2025, it was named Best IT Solution in the Labmate Awards for Excellence. The platform sits at the enterprise end of the LIMS market. It is not the cheapest option, and it is not the fastest to implement — but for regulated, multi-site laboratories that need deep configurability and long-term compliance capability, it has few peers. This article draws on LabWare’s official documentation, verified user reviews on G2 and Capterra, and publicly available press information. We have not accepted any payment or sponsorship from LabWare in connection with this article. At a glance Field Details Vendor LabWare, Inc. Founded 1987 Headquarters Wilmington, Delaware, USA Deployment options Four options: self-hosted (on-premise), cloud-hosted, SaaS (LabWare QAQC, ASSURE, GROW), and remotely hosted. Availability varies by region. Pricing Not publicly listed. Quote-based. SaaS tiers offered on OpEx subscription model; enterprise LIMS on custom licence. Key industries Pharma, biopharma, bioanalysis, biobanking, clinical research, CRO, environmental, food & beverage, forensics, oil & gas, mining & metals Compliance 21 CFR Part 11, GxP (GLP / GMP), ISO 17025, SOC 2 (SaaS infrastructure) ELN included Yes — LabWare ELN is a separate product, sold as part of the Enterprise Laboratory Platform alongside the LIMS G2 rating 4.5 / 5 — 100+ reviews. Named G2 Leader in LIMS, ELN, and Lab Inventory Management categories Capterra rating 4.4 / 5 — 7 reviews (small sample) Free trial No. Demo available on request. What LabWare LIMS does LabWare LIMS is a broad-based laboratory information management system designed to manage the complete testing lifecycle — from sample receipt through to final report. Its core functional scope, as documented on the vendor’s website, includes: One distinctive feature is LIMS Basic, LabWare’s proprietary scripting language. Users with configuration skills can write custom scripts to tailor workflows, calculations, and data controls without modifying the core software. Multiple G2 reviewers specifically highlight this as a key differentiator. It is also, however, a double-edged capability: customisations written in LIMS Basic create a dependency that can increase long-term service costs. Deployment options LabWare offers four distinct deployment models, which distinguishes it from many competitors that offer only cloud or only on-premise options: Compliance and regulatory support Regulatory compliance is one of LabWare’s primary selling points, and it is the area where the platform’s depth is most evident. Based on documentation published by LabWare and confirmed through third-party review sources: Validation LabWare’s SaaS products are described as “fully validated” and “pre-configured” by the vendor. For the enterprise (self-hosted or cloud-hosted) LIMS, validation remains the customer’s responsibility — though LabWare Global Services can support IQ/OQ/PQ engagements. Laboratories in regulated environments should clarify the scope of vendor-supplied validation documentation before purchase. Pricing LabWare does not publish pricing on its website. Pricing is available on request and is structured as a custom quote based on deployment model, number of users, industry, and required modules. For the SaaS products (QAQC, ASSURE, GROW), LabWare describes an OpEx-based subscription model with the flexibility to scale up or down on demand. For the enterprise LIMS, pricing follows a traditional licence-and-services model. Pricing note LabWare is consistently described by users and analysts as a premium-priced platform. One user review on Capterra states directly: “It’s not the cheapest (but still the best).” Implementation timelines reported in user reviews and analyst sources typically range from 6 to 12 months for enterprise deployments, with total cost of ownership — including configuration, validation, training, and ongoing admin — being a significant consideration. Budget for these costs explicitly when evaluating LabWare against lower-friction alternatives. Who LabWare LIMS is designed for LabWare serves a wide range of industries including pharmaceuticals, biopharma, bioanalysis, biobanking, clinical research, CROs, environmental testing, food and beverage, forensics, oil and gas, and mining — all confirmed via the vendor’s website. Named customers include GSK, Pfizer, Hershey, Caterpillar, and Chevron. In practice, the platform is most commonly chosen by: The SaaS products (QAQC, ASSURE, GROW) extend the platform’s accessibility to smaller labs that need validated, pre-configured workflows without the overhead of a full enterprise deployment. What users say The following themes are drawn from verified user reviews on G2 (100+ reviews, 4.5/5 average) and Capterra (4.4/5) (collected in April 2025). We have paraphrased themes rather than reproducing direct quotes at length. Frequently praised Frequently criticised Quick verdict Best for Large and mid-size regulated laboratories — particularly in pharma, biopharma, CRO, food, environmental, and industrial sectors — that need a deeply configurable, compliance-ready LIMS with a long track record and broad instrument integration. Also a credible option for smaller labs via the SaaS products (QAQC, ASSURE, GROW), which offer pre-validated, rapid-deployment alternatives to the full enterprise platform. Consider alternatives if Your lab has limited IT resources or no dedicated LIMS administrator. If you need to be live within weeks rather than months, or if budget constraints make a long implementation project impractical, faster-deploying platforms such as QBench, CloudLIMS, or Sapio Sciences may be a better fit. For early-stage biotech or academic research, Benchling or open-source tools offer a lower-friction starting point. Further reading Editorial note This article is based on information available from LabWare’s official website, press releases (including the March 2025 Pittcon announcement), verified user reviews on G2, Capterra, GetApp, and Software Advice, and independent analyst sources. No information has been included that could not be verified from at least one of these sources. LabWare has not reviewed, sponsored, or paid for this article. Last verified: April 2026.